Evidence map›Paper›PMID 31919579›Full record

Trial reportEuropean journal of pediatrics2020

Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.

Mónica Rodríguez, Valvanera Vozmediano, Aintzane García-Bea, Zoltán Novák, Anahí Yáñez, Cristina Campo, Luis Labeaga

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Mónica RodríguezDrug Modeling & Consulting, Dynakin S. L., Bilbao, Spain.
Valvanera VozmedianoDrug Modeling & Consulting, Dynakin S. L., Bilbao, Spain.
Aintzane García-BeaMedical Department, FAES FARMA, S. A., 48940, Leioa, Bizkaia, Spain. agarciabea@faes.es.
Zoltán NovákAranyklinika Egészségügyi és Innovációs Kft, Szeged, Hungary.
Anahí YáñezINAER-Investigaciones en Alergia y Enfermedades Respiratorias, Buenos Aires, Argentina.
Cristina CampoMedical Department, FAES FARMA, S. A., 48940, Leioa, Bizkaia, Spain.
Luis LabeagaMedical Department, FAES FARMA, S. A., 48940, Leioa, Bizkaia, Spain.
Faes Farma (Spain) · ESAdministración Nacional de Laboratorios e Institutos de Salud · ARSouth Great Plain Regional Innovation Agency · HU

Funding

FAES FARMA S.A N/A
6 · The paper itself

Abstract

Bilastine, a second-generation antihistamine, is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children aged ≥ 6 years. Pharmacokinetic data for children aged 6-11 years were extracted post hoc from a study in which children (2-11 years) with allergic rhinoconjunctivitis or urticaria received oral bilastine (10 mg/day). Maximum plasma concentration (C

Indexed as

Administration, OralAdultBenzimidazolesChildConjunctivitis, AllergicFemaleHistamine H1 Antagonists, Non-SedatingHumansMalePiperidinesUrticariaBenzimidazolesbilastineHistamine H1 Antagonists, Non-SedatingPiperidinesAllergic rhinoconjunctivitisBilastineChildrenPharmacokineticsSafetyUrticaria

Identifiers

PMID31919579
PMCPMC7160087
OpenAlexW2999263142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.